
U101-F Heavy Duty Flowmeter
This Flowmeter is to measure the exact volume of the dispensed fuel. which is designed for non-commercial use only. this flowmeter is reliable ,inexpensive, simple installation and easy calibration on the workplace.
Materials:
Body: teflon
seals: Buna-N
Technical Specifications:
Litre: 4 digits
Totalt: 8 digits
Flow rate range:20L~120L/min
Accuracy:±1%
Environmental condition:-40~~+70degree
Package:
Product ID Net Weight Cross Weight Dimension
U101-F 8kg/case of 1 9kg/case of 1 28×25×18cm/case of 1
we are committed to create the best workplace, encourage our staffs to put their own personalities into their jobs, and provide them a stage to show themselves.
eep job cuts at Schering to a minimum and base the
group s joint pharmaceuticals business in Berlin (meaning that the economically troubled capital would
contain at least one blue-chip firm).
By May 29th only 18.5% of Schering shares had been tendered into the takeover. Bayer extended its
deadline to June 14th, but without raising its offer price. Merck saw that as a chance either to make a
windfall or to wrest control of Schering, and started buying shares. On June 9th Bayer spent â‚?.9 billion
in the market to buy 23% of Scher fuel dispenser ing s stock to match Merck s 18.6%. The speculation was that Merck
wanted to force concessions out of Bayer, trading control for choice businesses or patents from Bayer or
Schering. But Merck was giving nothing away.
This week the spending continued. Merck s stake rose to 21.8%. Bayer felt obliged to go above its â‚?6
offer price. Allianz, which had already fuel dispenser pledged its 11% holding, sold it to Bayer outright for â‚?8 a share,
raising Bayer s stake to around 36%.
By crossing the 30% threshold Bayer was obliged to make a new offer for Schering at a market price. It
also filed a suit against Merck in New York, accusing it of flouting American capital-market rules by not
explaining its motive for buying the shares. Very soon, however, Merck s motive became clear it was
prepared to sell its stake to Bayer for â‚?9 a share, the price of Bayer s renewed bid. Bayer now has close
to 60% of Schering in its pocket. It has agreed with Merck to discuss “expanding and developing�co-
operation and has dropped the case in New York.
Merck is the world s oldest pharmaceuticals company. The Merck family owns 73% of it, and until this
year the firm was seen as conservative and typically German. The first surprise was its hostile bid, which
was fully supported by the family. The second was its silent assault on the Bayer takeover—behaviour
worthy of a “special situations�hedge fund.
The battle would have been less public were it not that all three companies, Baye fuel dispenser